A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression

This interesting letter by Murrough et al presented us with a dilemma.On the one hand it's an interesting case, with a good outcome.Treatment-resistant depression is a huge public health burden, and options are many but confusing.Add to the positives that intravenous ketamine is intriguing, with encouraging results and a mechanism that differs from traditional antidepressants.But this is only a single case, which means we can draw no conclusions.And some of the authors hold a use patent on ketamine (appropriately disclosed) and could profit from the agent if it is approved for marketing.On balance, we chose to share it with our clinical readership-with the duly noted caveats.